Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | MPL | P40238 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12870961 | 0.92 | HDAC1 (0.36) | HDAC1TBXAS1AKR1C3ACACB | |
| SCHEMBL12871092 | 0.89 | CYP1A2 (0.35) | CYP1A2CYP2C8HDAC1 | |
| SCHEMBL12871035 | 0.85 | HCRTR1 (0.35) | — | |
| SCHEMBL12871004 | 0.82 | HCRTR1 (0.36) | — | |
| SCHEMBL12871067 | 0.81 | AKR1C3 (0.33) | TBXAS1AKR1C3 | |
| SCHEMBL12871096 | 0.81 | HDAC1 (0.35) | HDAC1 | |
| SCHEMBL12870909 | 0.81 | IP6K1 (0.41) | CYP1A2CYP2C8HDAC1 | |
| SCHEMBL12870947 | 0.76 | HDAC1 (0.46) | HDAC1 | |
| SCHEMBL14532893 | 0.76 | HDAC1 (0.32) | CYP1A2CYP2C8HDAC1AKR1C3MPL | |
| SCHEMBL6448113 | 0.74 | CYP1A2 (0.42) | CYP1A2CYP2C8HDAC1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | CYP1A2 973/4885CYP2C8 2673/4885HDAC1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.